We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Stock Moves -0.25%: What You Should Know
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) closed the most recent trading day at $149.23, moving -0.25% from the previous trading session. This change was narrower than the S&P 500's daily loss of 0.3%. At the same time, the Dow lost 0.35%, and the tech-heavy Nasdaq lost 0.25%.
The world's biggest maker of health care products's stock has dropped by 3.51% in the past month, falling short of the Medical sector's loss of 3.43% and the S&P 500's gain of 1.09%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company's earnings report is expected on January 22, 2025. The company's upcoming EPS is projected at $1.99, signifying a 13.1% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $22.54 billion, up 5.37% from the year-ago period.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $9.93 per share and revenue of $88.84 billion. These results would represent year-over-year changes of +0.1% and -4.49%, respectively.
Investors should also note any recent changes to analyst estimates for Johnson & Johnson. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% lower. Johnson & Johnson presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Johnson & Johnson is currently being traded at a Forward P/E ratio of 15.06. This signifies a premium in comparison to the average Forward P/E of 14.37 for its industry.
It's also important to note that JNJ currently trades at a PEG ratio of 2.66. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 1.52.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 156, placing it within the bottom 38% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Stock Moves -0.25%: What You Should Know
Johnson & Johnson (JNJ - Free Report) closed the most recent trading day at $149.23, moving -0.25% from the previous trading session. This change was narrower than the S&P 500's daily loss of 0.3%. At the same time, the Dow lost 0.35%, and the tech-heavy Nasdaq lost 0.25%.
The world's biggest maker of health care products's stock has dropped by 3.51% in the past month, falling short of the Medical sector's loss of 3.43% and the S&P 500's gain of 1.09%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company's earnings report is expected on January 22, 2025. The company's upcoming EPS is projected at $1.99, signifying a 13.1% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $22.54 billion, up 5.37% from the year-ago period.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $9.93 per share and revenue of $88.84 billion. These results would represent year-over-year changes of +0.1% and -4.49%, respectively.
Investors should also note any recent changes to analyst estimates for Johnson & Johnson. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% lower. Johnson & Johnson presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Johnson & Johnson is currently being traded at a Forward P/E ratio of 15.06. This signifies a premium in comparison to the average Forward P/E of 14.37 for its industry.
It's also important to note that JNJ currently trades at a PEG ratio of 2.66. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 1.52.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 156, placing it within the bottom 38% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.